Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
LF.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XBB.1.10	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XBB.1.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BQ.1.1.61	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BQ.1.1.61	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.2.37	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.5.2.37	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.2.10	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.5.2.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XAS	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XAS	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.3.4	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.5.3.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
CN.2	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
CN.2	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.17	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.2.17	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BG.4	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BG.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BF.9	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BF.9	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.4.1.9	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.4.1.9	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.576	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.576	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.325	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.325	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.22	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.22	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.521	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.521	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.378	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.378	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.206	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.206	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.28	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.28	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.77	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
B.1.1.77	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.1.2.1	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
JN.1.2.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
HK.13.2	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
HK.13.2	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
HV.1.9	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
HV.1.9	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XBB.2.3.16	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
XBB.2.3.16	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.59	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
BA.2.59	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BR.2	N	US-CDC-N-2	TTACAAACATTGGCCGCAAA	20	40	29164	29183	F	-21115.5	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used